Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (S<underline>EASI</underline>DE CHINA)

被引：0
|
作者：
Zhang, Jianzhong [1 ]
Silverberg, Jonathan, I [2 ]
Guo, Jiawang [3 ]
Yun, Jili [3 ]
Pan, Wuban [3 ]
Wei, Zheng [4 ]
Collazo, Raul [4 ]
机构：
[1] Peking Univ, Dept Dermatol, Peoples Hosp, Beijing, Peoples R China
[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA
[3] Suzhou Connect Biopharmaceut Ltd, Taicang, Peoples R China
[4] Connect Biopharm LLC, San Diego, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
moderate-to-severe atopic dermatitis; rademikibart; CBP-201; therapy; IL-4R alpha;
D O I：
10.1093/bjd/ljae266.086
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
712
引用
收藏
页数：2
相关论文
共 32 条
  • [21] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Carrascosa, Jose Manuel
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [22] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
    Marquardt, Tzvetelina
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Serra-Baldrich, Esther
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Silverberg, Jonathan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
  • [23] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Wasel, Norman
    Thaci, Diamant
    French, Lars E.
    Conrad, Curdin
    Dutronc, Yves
    Gallo, Gaia
    Berggren, Lovisa
    Lacour, Jean-Philippe
    DERMATOLOGY AND THERAPY, 2020, 10 (04) : 663 - 670
  • [24] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Norman Wasel
    Diamant Thaçi
    Lars E. French
    Curdin Conrad
    Yves Dutronc
    Gaia Gallo
    Lovisa Berggren
    Jean-Philippe Lacour
    Dermatology and Therapy, 2020, 10 : 663 - 670
  • [25] Laboratory parameters in adolescent patients aged 12-17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial
    Paller, Amy
    Cork, Michael
    Hong, Chih-ho
    Soong, Weily
    Schneider, Shannon
    Lo, Hannah
    Pedersen, Line Rosendahl Meldgaard
    Vacko, Emilia
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II47 - II48
  • [26] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
    Jonathan I. Silverberg
    Melinda J. Gooderham
    Amy S. Paller
    Mette Deleuran
    Christopher G. Bunick
    Linda F. Stein Gold
    DirkJan Hijnen
    Brian M. Calimlim
    Wan-Ju Lee
    Henrique D. Teixeira
    Xiaofei Hu
    Shiyu Zhang
    Yang Yang
    Ayman Grada
    Andrew M. Platt
    Diamant Thaçi
    American Journal of Clinical Dermatology, 2024, 25 : 485 - 496
  • [27] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    Paller, Amy S.
    Deleuran, Mette
    Bunick, Christopher G.
    Gold, Linda F. Stein
    Hijnen, Dirkjan
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique D.
    Hu, Xiaofei
    Zhang, Shiyu
    Yang, Yang
    Grada, Ayman
    Platt, Andrew M.
    Thaci, Diamant
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (03) : 485 - 496
  • [28] CONJUNCTIVITIS IN ADOLESCENT PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH TRALO-KINUMAB UP TO WEEK 52: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL
    Wollenberg, Andreas
    de Bruin-Weller, Marjolein S.
    Thyssen, Jacob P.
    Beck, Lisa A.
    Simpson, Eric L.
    Imafuku, Shinichi
    Boguniewicz, Mark
    Kurbasic, Azra
    Soldbro, Lise
    Vest, Natacha Strange
    Amoudruz, Petra
    Paller, Amy S.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 35 - 35
  • [29] Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan, I
    Wollenberg, Andreas
    Legat, Franz J.
    Laquer, Vivian T.
    Armstrong, April W.
    Herranz, Pedro
    Naldi, Luigi
    Ahmad, Faiz
    Ulianov, Liliana
    Piketty, Christophe
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [30] 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn's Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction
    D'Haens, Geert
    Panaccione, Remo
    Pan, Julian
    Hisamatsu, Tadakazu
    Bossuyt, Peter
    Danese, Silvio
    Neimark, Ezequiel
    Song, Alexandra
    Liao, Xiaomei
    Wallace, Kori
    Zambrano, Javier
    Duan, W. Rachel
    Kligys, Kristina
    Dubinsky, Marla
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S497 - S498
1234